AnaptysBio, Inc. - Common Stock When Issued (ANABV)
Investment Snapshot
- P/B of 33.84 — trading above book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -257.2%
- Revenue growing at 157% annually
AnaptysBio, Inc. - Common Stock When Issued (ANABV) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $1.3 billion . Key value metrics: P/B ratio 33.84, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
AnaptysBio, Inc. - Common Stock When Issued — Fundamental Analysis Summary
On financial health, ANABV shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -257.2%.
StockPik's composite Value Score for ANABV is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ANABV shows revenue growing at 157% year-over-year, with earnings growing at 91%.